There are few studies that compare the safety of multiple induction therapies in simultaneous pancreas-kidney transplant (SPKT) patients. The purpose of this study is to compare basiliximab, thymoglobulin (ATG), and alemtuzumab according to HLA matching to assess allograft survival, rejection rate, and post-operative complications.
Details
Title
A single-center comparison of thymoglobulin, basiliximab, and alemtuzumab induction therapy in simultaneous pancreas-kidney transplant patients
Creator
Khan, Lubna : Oregon Health and Science University Elstrott, Ben : Oregon Health and Science University Olyaei, Ali : Oregon Health and Science University Lockridge, Joseph : Oregon Health and Science University Scott, David : Oregon Health and Science University
Meeting Name
Research Week, Oregon Health and Science University, 2020
